Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL)

被引：0
|
作者：
Brummendorf, T. H.
Cortes, J. E.
Kantarjian, H.
Gambacorti-Passerini, C.
Baccarani, M.
Kim, D.
Zaritskey, A.
Navarro, J.
Rapoport, A.
Dorlhiac-Llacer, P. E.
Milone, J.
Zanichelli, M.
Besson, N.
Leip, E.
Kelly, V.
Khoury, H. J.
机构：
[1] Rhein Westfal TH Aachen, Univ Klinikum Hamburg Eppendorf, Univ Klinikum Aachen, Aachen, Germany
[2] RWTH, Univ Klinikum Hamburg Eppendorf, Univ Klinikum Aachen, Hamburg, Germany
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Milano Bicocca, Monza, Italy
[5] Univ Bologna, Bologna, Italy
[6] Seoul St Marys Hosp, Seoul, South Korea
[7] Univ Pavlov, St Petersburg, Russia
[8] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[9] Greenebaum Canc Ctr, Baltimore, MD USA
[10] FMUSP, Hosp Clin, Sao Paulo, Brazil
[11] Inst Trasplante Medula Osea, La Plata, Buenos Aires, Argentina
[12] Univ Sao Paulo, Childrens Inst, Sao Paulo, Brazil
[13] Pfizer Global Res & Dev, Paris, France
[14] Pfizer Inc, Cambridge, MA USA
[15] Emory Univ, Sch Med, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.6535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6535
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).
    Khoury, H. J.
    Kim, D.
    Zaritskey, A.
    Apperley, J.
    Besson, N.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] BOSUTINIB FOR THIRD-LINE TREATMENT OF CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) FOLLOWING RESISTANCE OR INTOLERANCE TO IMATINIB (IM) AND DASATINIB (D)
    Gambacorti-Passerini, C.
    Cortes, J.
    Zaritskey, A.
    Bullorsky, E.
    Navarro, J.
    Khoury, H.
    Besson, N.
    McMullan, T.
    Arkin, S.
    Bruemmendorf, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 57 - 58
  • [3] Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib
    Khoury, H. Jean
    Kim, Dong-Wook
    Zaritskey, Andrey
    Gambacorti-Passerini, Carlo
    Hochhaus, Andreas
    Navarro, Juan
    Rapoport, Aaron P.
    Dorlhiac-Llacer, Pedro Enrique
    Zanichelli, Maria
    Kelly, Virginia
    Besson, Nadine
    McMullan, Trevor
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 391 - 391
  • [4] Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study
    Gambacorti-Passerini, Carlo
    Khoury, H. Jean
    Kantarjian, Hagop M.
    Lipton, Jeffrey H.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Matczak, Ewa M.
    Leip, Eric
    Noonan, Kay
    Bruemmendorf, Tim H.
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [5] Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
    Khoury, H. Jean
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Gambacorti-Passerini, Carlo
    Baccarani, Michele
    Kim, Dong-Wook
    Zaritskey, Andrey
    Countouriotis, Athena
    Besson, Nadine
    Leip, Eric
    Kelly, Virginia
    Bruemmendorf, Tim H.
    BLOOD, 2012, 119 (15) : 3403 - 3412
  • [6] Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
    F J Giles
    E Abruzzese
    G Rosti
    D-W Kim
    R Bhatia
    A Bosly
    S Goldberg
    G L S Kam
    M Jagasia
    W Mendrek
    T Fischer
    T Facon
    U Dünzinger
    D Marin
    M C Mueller
    Y Shou
    N J Gallagher
    R A Larson
    F-X Mahon
    M Baccarani
    J Cortes
    H M Kantarjian
    Leukemia, 2010, 24 : 1299 - 1301
  • [7] Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
    Giles, F. J.
    Abruzzese, E.
    Rosti, G.
    Kim, D-W
    Bhatia, R.
    Bosly, A.
    Goldberg, S.
    Kam, G. L. S.
    Jagasia, M.
    Mendrek, W.
    Fischer, T.
    Facon, T.
    Duenzinger, U.
    Marin, D.
    Mueller, M. C.
    Shou, Y.
    Gallagher, N. J.
    Larson, R. A.
    Mahon, F-X
    Baccarani, M.
    Cortes, J.
    Kantarjian, H. M.
    LEUKEMIA, 2010, 24 (07) : 1299 - 1301
  • [8] Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure.
    Lipton, Jeffrey Howard
    Cortes, Jorge E.
    Khoury, Hanna Jean
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Zeremski, Mirjana
    Bardy-Bouxin, Nathalie
    Shapiro, Mark
    Leip, Eric
    Gambacorti-Passerini, Carlo
    Bruemmendorf, Tim H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
    Cortes, Jorge E.
    Khoury, Hanna J.
    Kantarjian, Hagop M.
    Lipton, Jeff H.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Matczak, Ewa
    Leip, Eric
    Noonan, Kay
    Bruemmendorf, Tim H.
    Gambacorti-Passerini, Carlo
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (12) : 1206 - 1214
  • [10] Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update
    Khoury, H. Jean
    Gambacorti-Passerini, Carlo
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Marin, David
    Dorlhiac-Llacer, Pedro E.
    Zaritskey, Andrey
    Navarro, Juan
    Bullorsky, Eduardo O.
    Assouline, Sarit
    Leip, Eric
    Kelly, Virginia
    Turnbull, Kathleen
    Besson, Nadine
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
12345